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ABSTRACT 
A clinical trial was undertaken to evaluate the Anti depressant efficacy of Newer Antidepressant 
Mirtazapine in the treatment of major Depression in 39 patients in an O.P.D. setup. In addition to this 
clinical acceptability and safety profile of Mirtazapine as compared to that of Amitriptyline was also 
assessed. Mitazapine usually described as Noradrenergic and specific serotonergic Anti depressant 
(NaSSA). Patients aged 18-65 years who fulfilled the diagnostic criteria for a single or recurrent 
major Depressive disorder (as defined by DSM IV) for a minimum of 2 weeks were enrolled at our 
study centre. Patient assessment were conducted at screening, baseline, end of week 1, week 2, 
week 3, week 4, week 5 & end of week 6 for the efficacy & safety Parameters; HRSD, CGI, Adverse 
event follow up, BP & Pulse. Three level statistical analysis were performed on all efficacy measures 
including ANOVA (An Analysis of variance). The result indicates that mirtazapine is effective in the 
treatment of major depression at the dosages range of 15-45 mg/day and it has efficacy equivalent to 
thahofthe standard TCA Amitriptyline, albeit, with a substantially better tolerability profile. 
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Mirtazapine is an antidepressant with a directly blocked by mirtazapine, serotonin acts 
unique pharmacological profile, usually described at the other receptor subtypes, particularly 
as noradrenergic and specific serotonergic 5-HT1A. The resulting increase in both 
antidepressant (NaSSA). It is an antagonist of noradrenergic and serotonergic neurotransmission 
central a, auto and heteroreceptors with a marginal systems is thought to contribute to the 
affinity for a, - adrenoreceptors. The blockade of antidepressant activity of mirtazapine (DSM-
presynaptic inhibitory a, autoreceptors causes iv.1994; Bremner,1995). Mirtazapine has little 
an increase in the release of noradrenaline. The affinity for D, and D2 receptors and has marginal 
subsequent excitation of a, receptors by affinity for muscarinic cholinergic receptors, 
noradrenaline which facilitate serotonin (5-HT) cell Although the compound has affinity for H, 
firing, and the direct blockade by mirtazapine of histaminergic receptors, its sedating effects are 
inhibitory a2 heteroreceptors located on 5-HT partially counterbalanced by its action on the 
terminals lead to an increase in the release of noradrenergic system at usual therapeutic 
serotonin. As both 5-HT2 and 5-HT3 receptors are dosages (DSM-IV1994; Bremner, 1995; Ciaollors 
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& Mutazapine 1996, Claghorn & Leseno, 1995). 
The aims of the present study were-
1. To evaluate the antidepressant efficacy of 
mirtazapine in the treatment of major Depression 
in Indian Population and 
2. To assess the clinical acceptability and safety 
of mirtazapine as compared to that of 
amitriptyline. 
MATERIAL AND METHOD 
Selection of patients. Patients aged 18-65 years, 
who fulfilled the diagnostic criteria for a single or 
recurrent major depressive disorder, as defined 
by DSM-IV for a minimum of 2 weeks, were 
enrolled at our study centre. The nature of 
depressive disorder was moderate or severe, 
without mood incongruent psychotic features. 
Pregnant or nursing women were not included in 
the study; and women of child bearing age were 
advised to use appropriate birth control methods 
during the trial period. All the patients signed an 
informed consent prior to the inclusion in the study. 
Patients with a minimum total score of 15 
on 17 item Hamilton Rating Scale for Depression 
(HRSD) at both the initial screening and 
pretreatment baseline were allowed to participate 
in the study. Only OPD patients were recruited 
for the study. 
Patients with a history of alcohol 
dependence or substance abuse in the past 2 
years, demonstrated a placebo response during 
screening (i.e> 20% decrease in HRSD score 
between screening and baseline) or patients 
displayed acute or unstable medical problem were 
not allowed to enter the study. The other 
exclusion criteria included hypersensitivity to 
SSRIs, previous use of mirtazapine, history of 
seizures, concomitant psychotropic medication, 
bipolar depression, other significant organic 
disease, clinically significant laboratory 
abnormalities, or other primary psychiatric 
diagnosis. 
Trial Design: Patients meeting the initial inclusion 
criteria entered a one week placebo screening 
phase. At the end of one week placebo washout 
period, patients returned for their final screening 
procedures. All the patients who satisfied the 
inclusion and exclusion criteria were then 
randomized to either mirtazapine or amitriptyline 
treatment in an open, parallel group study design. 
The study drug was supplied in bottles 
containing seven day supply. Patients in the 
mirtazapine group received mirtazapine 15 mg 
tablets, and patients in the amitriptyline group 
received amitriptyline 25 mg tablets. 
Target dosage ranges of 15 mg to 45 mg 
daily for mirtazapine and 25 mg to 150 mg for 
amitriptyline were predetermined, and the lowest 
effective does was to be maintained throughout 
the 6 week portion of the study. 
Clinical Laboratory Investigations: Clinical 
laboratory investigations (urine analysis, 
haematology, biochemistry, ECG and chest X-ray) 
were conducted at screening and at the end of 
the study. All reguired clinical laboratory 
investigations were done by approved professional 
laboratory. 
Storage: During the trial, the trial drug was kept 
in a secured place The trial drug was not supplied 
to any one except the co-investigators or deputy 
involved in the study. Detailed account to use of 
the drug with date and patient number was 
maintained. Unused drug was returned to the 
monitor after the study was completed. 
Associated Treatment: Full information concerning 
the name, dosage, duration of the other 
concomitant therapy was recorded. 
Adverse Event management: At each follow-up 
visit, the patients were asked for any possible 
adverse events. Any reported side effects were 
reported in the adverse event form. Any serious/ 
life-threatening side effects were to be informed 
to the sponsors representative immediately. 
Details of adverse event management (Corrective 
therapy, change in dosage, withdrawal of drug, 
etc.), were clearly reported in the case record form. 
Also the severity of side effects were also 
mentioned 
The number and percentage of patients 
experiencing each specific event for Treatment-
Emergent-Signs and Symptoms(TESS) (defined 
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as experience that appeared for the first time 
during the study) were calculated for both 
treatment groups. The number and percentage of 
patients reporting any adverse experience were 
computed for both the treatment groups. 
Patient Assessment: Patient assessments were 
conducted at screening, baseline, end of week 1, 
week 2, week 3, week 4, week 5 and end of week 
6 for the efficacy and safety parameters; 
HRDS.CGI , adverse event follow-up , B.P. and 
pulse. 
General physical examination and medical 
and psychiatric history were conducted at 
screening only. Clinical laboratory evaluations 
were conducted at screening at the the end of 
trial. 
The primary efficacy variables were the 17-
item HRSD and the CGI- Improvement scale. 
Responder status was defined as improvement 
during treatment of > 50% on the HRSD total 
scores. In the case of CGI- improvement scale, 
responder status was defined as improvement to 
a score of 1 (very much improved) or 2 (much 
improved). A sustained response was defined as 
improvement that once observed persisted until 
the end of trial. A final 17-item HRSD total score 
of 8 or less defined remission. 
Statistical Methods: Three basic statistical 
analysis were performed on all efficacy 
measures. An analysis of variance (ANOVA) for 
baseline ratings to assess the equivalence of the 
treatment groups at the beginning of the study. 
ANOVA of pre-treatment versus post-treatment to 
examine the response produced by each drug 
over time. An ANOVA for each assessment to 
evaluate the differences between the treatment 
groups. 
RESULTS 
Patient Disposition: Forty patients who 
fulfilled the inclusion criteria were recruited for the 
trial. At the start of the drug period, the mirtazapine 
group consisted of 21 patients, and the 
amitriptyline group, 18 patients. All randomized 
patients who received study drug comprised the 
intent-to-treat safety population. There were 3 drop 
outs in mirtazapine group resulting in an intent-to 
treat efficacy population of 18 mirtazapine treated 
and 18 amitriptyline treated patients. 
Demographic and Baseline Characteristics: 
Physically healthy patients only were enrolled for 
the study. No significant differences were detected 
between mirtazapine and amitriptyline groups on 
any demographic, diagnostic or psychiatric history 
variables, as shown in Table-ll. 
Patient Treatment: The average daily dose range 
of mirtazapine at the end of the trial was 
22.89±10.45 mg and for amitriptyline the same 
was 75.00±0.00 mg (Dose range 25-150mg). 
Primary Efficacy 
Hamilton Rating Scale for Depression (HRSD): 
Mirtazapine group showed a slightly higher level 
of depression than amitriptyline as measured by 
the HRSD total score at baseline. A summary of 
total score changes from baseline to end point in 
HRSD is given in table 1. 
By the end of week 3, mirtazapine group 
showed a mean decrease of more than 18.19 
points on the HRSD total score, while the 
amitriptyline group showed a mean decrease of 
10.66. By the end of week-6 (endpoint) the total 
reductions in the HDRS score as compared to 
baseline were 26.20 and 14.44 for mirtazapine and 
amitriptyline respectively. The percentage 
reduction in the mean HRSD score for mirtazapine 
was 89.91% while that for amitriptyline was 
54.04%. 
Clinical Global Improvement Scale (CGI) 
Both mirtazapine and amitriptyline groups 
were comparable in total CGI score at baseline. 
A summary of total score changes from baseline 
to end point in CGI is given in Table-ll. 
The percentage reduction in the mean CGI 
score for mirtazapine was 70.78% while that for 
amitriptyline was 43.11%. 
Tolerability: 
Treatment emergent adverse events were 
reported by 28.57% (N=6) of mirtazapine treated 
patients and 94.45% (N=17) of amitriptyline treated 
patients. The most common events are 
summarized in Table-VI. The majority of all adverse 
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TABLE 1 
MEAN HRSD TOTAL SCORES (INTENT-TO TREAT PATIENT SAMPLE) 
Variable 
HRSD 
Score 
Mirtazepine 
Amitriptyline 
Variable 
CGI 
Score 
Mirtazepine 
Amitriptyline 
Baseline 
score 1 
29.14± 21.05± 
5.47 6.44 
26.72* 24.50± 
6.42 6.82 
2 
15.80± 
5.66 
20.50± 
5.67 
End of week 
3 
10.95± 
6.28 
16.06± 
5.13 
4 
6.72± 
4.13 
14.11± 
5.14 
TABLE 2 
MEAN CGI TOTAL SCORES (INTENT-TO TREAT PATIENT SAMPLE) 
Baseline 
score 1 
4.621 3.24 ± 
1.07 1.34 
4.50 ± 3.89± 
1.15 1.02 
2 
2.40± 
0.68 
3.33± 
0.91 
End of week 
3 
2.05 ± 
0.62 
2.67± 
0.59 
4 
1.72± 
0.57 
2.72± 
0.57 
5 
4.56± 
3.50 
13.11* 
5.22 
i 
5 
1.61± 
0.50 
2.67± 
0.97 
6 
294* 
2.88 
12.28* 
5.09 
6 
1.35* 
0.49 
2.56* 
0.78 
events in both treatment groups were mild to 
moderate and did not lead to discontinuation of 
the treatment. 
Two mirtazapine treated patients (9.52%) 
each reported headache and nausea; one (4.76%) 
each reported sedation, vertigo, anxiety, sleep 
disorder and dyspepsia. Twelve (66.67%) 
amitriptyline treated patients reported of dry 
mouth; eleven (61.11%) reported of constipation; 
five (27.78%) each reported of sedation.vertigo and 
urinary retention; two (11.11%) reported sleep 
disorder and impotence; one (5.56%) reported 
each of headache, giddiness, anxiety, blurring of 
vision, tremor, anorexia, postural hypotension, 
bitterness of mouth, abdominal pain and diarrhoea. 
Overall Evaluation of tolerability by the 
investigator and the patient. 
At the end of the study an overall 
assessment of tolerability was made by the 
investigator as well as the patient, this 
assessment was based on the number and 
severity of adverse effects and likelihood of a 
causal relationship, the drug could be assessed 
as having excellent, good, moderate or bad 
tolerability. 
In the mirtazapine group as per the 
investigator's evaluation,33.34% (N=6) of the 
patients who completed the treatment showed 
excellent tolerability and 66.67% (N=12) exhibited 
a good tolerability, mild adverse event was reported 
in 6 patients (28.57%). 
In the amitriptyline group as per the 
investigator's evaluation about 38.88% (N=7) 
showed a good tolerability, 55.56% (N=10) showed 
a moderate tolerability and 5.56% (N=1) showed 
a bad tolerability mild to moderate adverse event 
was observed in 17 patients (94 44%). 
In the overall evaluation of tolerability by 
the patient,27.78% (N=5) of the patients who 
completed the treatment in the mirtazapine group 
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stated the drug to have an excellent tolerability 
and 72.23% (N=13) stated it to have a good 
tolerability. 
In the amitriptyline group 33.34% (N=6) 
reported a good tolerability, 61.11% (N=11) 
reported a moderate tolerability and 5.56% (N=1) 
reported a bad tolerability. 
Overall Evaluation of Efficacy by the Investigator 
For the overall assessment of the treatment 
acceptability and efficacy the protocol defined four 
categories, very good, good, moderate, unchanged 
or worse. 
TABLE 3 
NUMBER/PERCENTAGE OF PATINETS REPORTING 
ADVERSE EVENT 
Adverse Mirtazapine Amitriptyline 
Event (N=21) (N=18) 
Number % Number % 
In the mirtazapine group, 66.67% (N=12) 
of the patients who completed the treatment 
showed very good response, 27.78% (N=5) 
showed good response and 5.56% (N=1) showed 
moderate response. 
In the amitriptyline group 44.45% (N=5) 
showed good response; 50.00% (N=9) showed 
moderate response and 5.56% (N=1) were non 
responders. 
DISCUSSION 
The result of the study indicates that 
mirtazapine is effective in the treatment of 
depression at the dosage range of 15-45 mg/day. 
The average dose used at the end of the study 
was 22.89±10.45 mg/day. 
In several studies mirtazapine has 
demonstrated efficacy equivalent to that of other 
commonly prescribed tricyclic antidepressants, 
such as amitriptyline (Hamilion,1960; 
Khan,1995;MarTlhla et al.,1995; Montgomery, 
1995; Mullin etal.,1996). There is some evidence 
of faster onset of action with mirtazapine that with 
the selective serotonin reuptake inhibitors (SSRIs). 
Mirtazapine was more effective than the SSRI 
fluoxetine at weeks 3 and 4 of therapy and it was 
also more effective than paroxetine and citalopram 
at weeks 1 and 2, respectively, in short-term 
assessments ( 6 to 8 weeks). Mirtazapine had 
equivalent efficacy to the SSRIs at study end-
point. Preliminary data suggest that the drug may 
be effective as an augmentation or combination 
therapy in patients with refractory depression. 
Mirtazapine displays a favourable tolerability 
profile, with virtually no anticholinergic, 
antiadrenergic or serotonergic adverse events. 
Complaints of drowsiness, appetite increase, dry 
mouth and weight gain were the only adverse 
events reported significantly more frequently than 
with placebo (Zivkov & Jongh,1996). 
Large differences in efficacy between both 
the treatment groups were not observed, the 
primary treatment outcome of this study suggest 
that mirtazapine is equally efficacious as 
amitriptyline. Mirtazapine produced some initial 
therapeutic benefit over amitryptiline as measured 
by HRSD score throughout the six-week study. 
In the secondary efficacy variable (CGI) also 
mirtazapine showed benefit. Also mirtazapine 
showed significant clinical response at the end of 
three weeks of treatment. In addition to overall 
improvement in depressive symptoms and 
depressed mood, both mirtazapine and 
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amitriptyline were equally effective in reducing 
anxiety, sleep and vegetative disturbances 
associated with depression, as assessed by 
changes in respective HRSD factors. The 
response and recovery time with Mirtazapine was 
relatively shorter as compared to Amitriptyline. 
Considering the side effect profile, 
mirtazapine was better tolerated than 
amitriptyline. Only six patients (28.57%) reported 
side effects. However only one patient had to 
discontinue the study due to the suicidal attempt 
& subsequently had to switch over to ECT. In the 
amitriptyline group, 17 patients (94.45%) reported 
side effects. Dry mouth, constipation, sedation, 
vertigo and urinary retention were the major 
reported side effects with amitriptyline. 
Our study demonstrated that mirtazapine 
has efficacy equivalent to that of the standard 
tricyclic drug amitriptyline in the treatment of 
| moderately to severely depressed outpatients but 
' with a substantially better tolerability profile. 
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